A Study of RVT-1401 in Myasthenia Gravis (MG) Patients

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2019
The purpose of the current study is to assess safety/tolerability and key pharmacodynamic (PD) effects that are considered to be associated with clinical benefit (reduction of total IgG and anti‐AChR‐IgG) in Myasthenia Gravis patients following treatment with RVT‐1401 (also known as IMVT‐1401) compared to placebo.
Epistemonikos ID: 951544980cb97b8ded8961f507f17d2287b30017
First added on: May 22, 2024